IGCS 2022 Master Session: Uterine Cancer - Management of Endometrial Cancer in The Molecular Era

Description

Held on September 29, 2022 at the IGCS 2022 Annual Global Meeting in New York City, USA. In this session describes the exciting transformation of the endometrial cancer landscape in the last several years, moving to molecular classification for aid in pathological categorization and providing prognostic and predictive information with which to guide management and clinical trials. Strategies for implementation of molecular classification in both low and high resource settings will be shared, as well as when additional molecular or pathological parameters might add value. Current challenges or as yet unanswered questions in endometrial cancer management will be addressed.

Master Session: Uterine Cancer - Management of Endometrial Cancer in The Molecular Era
Chair(s)	Glauco Baiocchi (Brazil) Ramez N. Eskander (United States of America) Graziela Zibetti Dal Molin (Brazil) Jessica N. McAlpine (Canada) Mansoor R. Mirza (Denmark)
PANEL 1: SURGICAL CONTROVERSIES IN EARLY-STAGE DISEASE	Moderated by Jessica N. McAlpine (Canada)
Should we avoid uterine manipulator in MIS for endometrial cancer?	Mario Leitao (USA)
Suspicious lymph node during sentinel node biopsy. Is there a role for systematic lymphadenectomy?	Emma C. Rossi (USA)
Should all ITC and micrometastasis receive adjuvant treatment?	Andrea Mariani (USA)
Can lymph node staging ± other surgical decisions be tailored in context molecular subtype?	Amy Jamieson (Canada)
PANEL 1 - DISCUSSION	Jessica N. McAlpine (Canada) Mario M. Leitao (USA) Emma C. Rossi (USA) Andrea Mariani (USA) Amy Jamieson (Canada)
PANEL 2: CONTROVERSIES IN ENDOMETRIAL CANCER	Moderated by Graziela Zibetti Dal Molin
How can I get molecular classification/subtyping for patients? Considerations for both low and high resource settings?	Naveena Singh (Canada)
DEBATE: What should be the best approach for endometrioid (grade 3) with small volume long term relapsed disease?
DEBATE: Pro for surgery	Nadeem R. Abu-Rustum (USA)
DEBATE: Pro for SBRT	Anuja Jhingran (USA)
DEBATE: Pro for systemic treatment	Domenica Lorusso (Italy)
Are we ready to incorporate molecular classification into clinical practice and treatment planning?	Shannon N. Westin (USA)
PANEL 2 - DISCUSSION	Graziela Zibetti Dal Molin (Brazil) Naveena Singh (Canada) Nadeem R. Abu-Rustum (USA) Anuja Jhingran (USA) Domenica Lorusso (Italy) Shannon N. Westin (USA)
PANEL 3: NEW TREATMENT OPTIONS FOR ADVANCED AND METASTATIC DISEASE	Moderated by Helen MacKay
Biomarkers in clinical practice for endometrial cancer: MMR status, TMB, PDL-1, TP53mut, ERpos, HER2+ : How can we improve outcomes?	Ana Oaknin (Spain)
What is the concept of platinum-resistance and platinum-free interval in endometrial cancer?	Vicky Makker (United States of America)
PANEL 3 - DISCUSSION	Helen J. MacKay (Canada) Ana Oaknin (Spain) Vicky Makker (USA)

Summary


Availability:	On-Demand


Cost:	FREE

Create Account

Recommended

Radical Hysterectomy - Surgical Film Festival

$0.00 - $50.00

Preinvasive Disease Program

Preinvasive Disease Program is an IGCS member benefit.

FREE

Endometrial Cancer Tumor Board: Matching the right therapy to the right patient

FREE

Obstacles and solutions for worldwide implementation of the Molecular Endometrial Carcinoma Classification - Webinar

FREE

Complication Management - Surgical Film Festival - Webinar

$0.00 - $50.00

Radical Hysterectomy - Surgical Film Festival - Webinar

$0.00 - $50.00

Multidisciplinary Approach to Treating Advanced Endometrial Cancer

FREE

Obstacles and solutions for worldwide implementation of the Molecular Endometrial Carcinoma Classification

FREE

PANEL 1: SURGICAL CONTROVERSIES IN EARLY-STAGE DISEASE